Overview

• Johnson & Johnson is the latest drugmaker to sue the US government over the Medicare drug price negotiation program.
• The program allows Medicare to negotiate lower drug prices, which drugmakers argue will hurt innovation and profits.
• J&J claims the law is unconstitutional and could impact patient access and quality of care.
• The Biden administration aims to lower healthcare costs for seniors through the negotiations.
• Other major drugmakers like Merck and Bristol Myers Squibb have filed similar lawsuits against the program.